OSENI Drug Profile, 2023

OSENI Drug Profile, 2023
Author: DrugPatentWatch
Publisher: DrugPatentWatch.com
Total Pages: 98
Release: 2023-08-15
Genre: Medical
ISBN: 1934899887

OSENI Drug Profile, 2023

This report focuses on OSENI and covers the following critical aspects of this drug:

  • United States patents
  • Expired United States patents
  • District Court patent litigation
  • European supplementary protection certificates (SPCs)
  • Drug prices
  • Finished product suppliers
  • Raw active pharmaceutical ingredient (API) sources

NESINA Drug Profile, 2023

NESINA Drug Profile, 2023
Author: DrugPatentWatch
Publisher: DrugPatentWatch.com
Total Pages: 100
Release: 2023-08-15
Genre: Medical
ISBN: 1934899852

NESINA Drug Profile, 2023

This report focuses on NESINA and covers the following critical aspects of this drug:

  • United States patents
  • Expired United States patents
  • FDA Paragraph IV patent challenges
  • District Court patent litigation
  • European supplementary protection certificates (SPCs)
  • Clinical trials
  • Drug prices
  • Finished product suppliers
  • Raw active pharmaceutical ingredient (API) sources

EDURANT Drug Profile, 2023

EDURANT Drug Profile, 2023
Author: DrugPatentWatch
Publisher: DrugPatentWatch.com
Total Pages: 100
Release: 2023-08-15
Genre: Medical
ISBN: 1934899860

EDURANT Drug Profile, 2023

This report focuses on EDURANT and covers the following critical aspects of this drug:

  • United States patents
  • Expired United States patents
  • District Court patent litigation
  • European supplementary protection certificates (SPCs)
  • Clinical trials
  • Drug prices
  • Finished product suppliers
  • Raw active pharmaceutical ingredient (API) sources

KAZANO Drug Profile, 2023

KAZANO Drug Profile, 2023
Author: DrugPatentWatch
Publisher: DrugPatentWatch.com
Total Pages: 100
Release: 2023-08-15
Genre: Medical
ISBN: 1934899844

KAZANO Drug Profile, 2023

This report focuses on KAZANO and covers the following critical aspects of this drug:

  • United States patents
  • Expired United States patents
  • FDA Paragraph IV patent challenges
  • District Court patent litigation
  • European supplementary protection certificates (SPCs)
  • Clinical trials
  • Drug prices
  • Finished product suppliers

Stroke Genetics

Stroke Genetics
Author: Hugh S. Markus
Publisher:
Total Pages: 362
Release: 2003
Genre: Medical
ISBN: 0198515863

Stroke is a major cause of death and the major cause of adult neurological disability in most of the world. Despite its importance on a population basis, research into the genetics of stroke has lagged behind that of many other disorders. However, the situation is now changing. An increasing number of single gene disorders causing stroke are being described, and there is growing evidence that polygenic factors are important in the risk of apparently "sporadic" stroke. Stroke Genetics provides an up-to-date review of the area, suitable for clinicians treating stroke patients, and both clinical and non-clinical researchers in the field of cerebrovascular disease. The full range of monogenic stroke disorders causing cerebrovascular disease, including ischaemic stroke, intracerebral haemorrhage, aneurysms and arteriovenous malformations, are covered. For each, clinical features, diagnosis, and genetics are described. Increasing evidence suggest that genetic factors are also important for the much more common multifactorial stroke; this evidence is reviewed along with the results of genetic studies in this area. Optimal and novel strategies for investigating multifactorial stroke, including the use of intermediate phenotypes such as intima-media thickness and MRI detected small vessel disease are reviewed. The book concludes by describing a practical approach to investigating patients with stroke for underlying genetic disorders. Also included is a list of useful websites.

Type 2 Diabetes

Type 2 Diabetes
Author: Anthony Barnett
Publisher: Oxford University Press
Total Pages: 175
Release: 2012-10-25
Genre: Medical
ISBN: 0199596174

This second edition has been updated throughout to aacount for the latest trial data, including new chapters on pathophysiology, and interpretation of recent clinical trials. This pocketbook is a concise, practical guide to the diagnosis, assessment and management of Type 2 Diabetes aimed at clinicians, GPs and nurse specialists.

Regulating Pharmaceuticals In Europe: Striving For Efficiency, Equity And Quality

Regulating Pharmaceuticals In Europe: Striving For Efficiency, Equity And Quality
Author: Mossialos, Elias
Publisher: McGraw-Hill Education (UK)
Total Pages: 390
Release: 2004-06-01
Genre: Education
ISBN: 0335214657

"This thoughtful and comprehensive book represents the best work I have seen on the current situation concerning medication policies in the EU. It is not just that this is a very up-to-date compendium of facts and data across a wide variety of domains that impact on pharmaceutical regulation. The book is also strong on analysis of those facts as well." Jerry Avorn, Harvard Medical School. "This book offers a comprehensive examination of approaches to manage pharmaceutical expenditures in Europe. It is a must-read for those who seek to understand and navigate the changing regulatory environment for medicines in the European Union." Bernie O'Brien, McMaster University, Canada. The rising cost of pharmaceutical expenditures in many European countries is of concern to governments required to make effective use of health care budgets. Taking a broad perspective that encompasses institutional, political and supranational aspects of pharmaceutical regulation, this book examines approaches used to manage pharmaceutical expenditure across Europe and what impact these strategies have had on efficiency, quality, equity and cost of pharmaceutical care.Regulating Pharmaceuticals in Europe is an important book for students of health policy, regulation and management, and for health managers and policy makers. The editors: Elias Mossialos is Brian Abel-Smith Professor of Health Policy at the London School of Economics and Political Science and a Research Director of the European Observatory on Health Systems and Policies. Monique Mrazek is a Health Economist (Europe and Central Asia region) for the World Bank and formerly a Research Officer in Health Economics for the European Observatory on Health Systems and Policies. Tom Walley is Professor of Clinical Pharmacology at the University of Liverpool and Director of the UK National Health Technology Assessment Programme. Contributors:Julia Abelson, Christa Altenstetter, Vittorio Bertele’, Christine Bond, Marcel L. Bouvy, Colin Bradley, Steve Chapman, Anna Dixon, Michael Drummond, Pierre Durieux, Edzard Ernst, Armin Fidler, Eric Fortess, Richard Frank, Silvio Garattini, Leigh Hancher, Ebba Holme Hansen, Steve Hudson, Kees de Jonchere, Panos Kanavos, Sjoerd Kooiker, Jean-Marc Leder, Graham Lewis, Donald W. Light, Alistair McGuire, Elias Mossialos, Monique Mrazek, Maria Pia Orru', Govin Permanand, Guenka Petrova, Munir Pirmohamed, Dennis Ross-Degnan, Frans Rutten, Steven Soummerai, David Taylor, Sarah Thomson, Tom Walley.

The Hypothalamus-Pituitary-Adrenal Axis

The Hypothalamus-Pituitary-Adrenal Axis
Author:
Publisher: Elsevier
Total Pages: 413
Release: 2008-09-12
Genre: Science
ISBN: 0080559360

The hypothalamic-pituitary-adrenal axis controls reactions to stress and regulates various body processes such as digestion, the immune system, mood and sexuality, and energy usage. This volume focuses on the role it plays in the immune system and provides substantive experimental and clinical data to support current understanding in the field, and potential applications of this knowledge in the treatment of disease. - Evidence presented in this book suggests that the nervous, endocrine, and immune systems form the Neuroendoimmune Supersystem, which integrates all the biological functions of higher organisms both in health and disease for their entire life cycle - Contributors include both the scientists who initiated the work on the HPA axis and on the autonomic nervous system, and those who joined the field later

World Report on Child Injury Prevention

World Report on Child Injury Prevention
Author: M. M. Peden
Publisher: World Health Organization
Total Pages: 233
Release: 2008
Genre: Business & Economics
ISBN: 9241563575

Child injuries are largely absent from child survival initiatives presently on the global agenda. Through this report, the World Health Organization, the United Nations Children's Fund and many partners have set out to elevate child injury to a priority for the global public health and development communities. It should be seen as a complement to the UN Secretary-General's study on violence against children released in late 2006 (that report addressed violence-related or intentional injuries). Both reports suggest that child injury and violence prevention programs need to be integrated into child survival and other broad strategies focused on improving the lives of children. Evidence demonstrates the dramatic successes in child injury prevention in countries which have made a concerted effort. These results make a case for increasing investments in human resources and institutional capacities. Implementing proven interventions could save more than a thousand children's lives a day.--p. vii.

Childhood Glaucoma

Childhood Glaucoma
Author: R.N. Weinreb
Publisher: Kugler Publications
Total Pages: 290
Release: 2013-11-07
Genre: Medical
ISBN: 9062992390

Preface Childhood is the topic of the ninth World Glaucoma Association Consensus. There has been only sparse attention to the diagnosis and treatment of childhood glaucoma. Both pediatric ophthalmologists and glaucoma specialists provide care for such children. In some instances, they manage these individuals alone and, in others, the management is shared. For this consensus, the participation of both groups was solicited. The global faculty, consisting of leading authorities on the clinical and scientific aspects of childhood glaucoma, met in Vancouver on July 16, 2013, just prior to the World Glaucoma Congress, to discuss the reports and refine the consensus statements. As with prior meetings, it was a daunting task to seek and obtain consensus on such a complicated and nuanced subject. It is unclear how each of us decides how we practice, and evidence to guide us often is sparse. It is remarkable how few high level studies have been conducted on the management of childhood glaucoma. Hence, this consensus, as with the others, is based not only on the published literature, but also on expert opinion. Although consensus does not replace and is not a surrogate for scientific investigation, it does provide considerable value, especially when the desired evidence is lacking. The goal of this consensus was to provide a foundation for diagnosing and treating childhood glaucoma and how it can be best done in clinical practice. Identification of those areas for which we have little evidence and, therefore, the need for additional research also was a high priority. We hope that this consensus report will serve as a benchmark of our understanding. However, this consensus report, as with each of the others, is intended to be just a beginning. It is expected that it will be revised and improved with the emergence of new evidence. Robert N. Weinreb, Chair